Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 17/20 | 0.53 |
| ▸ | TGFBR1 | P36897 | 9/20 | 0.52 |
| ▸ | AURKA | O14965 | 8/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.52 |
| ▸ | ABL1 | P00519 | 2/20 | 0.50 |
| ▸ | BCR | P11274 | 2/20 | 0.50 |
| ▸ | CHUK | O15111 | 1/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13525284 | 0.85 | JAK2 (0.51) | JAK2PDPK1TGFBR1AURKAAURKB | |
| SCHEMBL13525283 | 0.85 | JAK2 (0.51) | JAK2PDPK1TGFBR1AURKAAURKB | |
| SCHEMBL13525178 | 0.85 | JAK2 (0.52) | JAK2PDPK1TGFBR1AURKAAURKB | |
| SCHEMBL12907205 | 0.83 | JAK2 (0.64) | JAK2PDPK1TGFBR1AURKAAURKB | |
| SCHEMBL13525282 | 0.83 | PDPK1 (0.51) | JAK2PDPK1TGFBR1AURKAAURKB | |
| SCHEMBL6479941 | 0.82 | JAK2 (0.72) | JAK2PDPK1TGFBR1AURKAAURKB | |
| SCHEMBL497271 | 0.82 | PDPK1 (0.60) | JAK2PDPK1TGFBR1AURKAAURKB | |
| SCHEMBL4491663 | 0.78 | PDPK1 (0.71) | JAK2PDPK1TGFBR1AURKAAURKB | |
| SCHEMBL13986221 | 0.78 | PDPK1 (0.66) | JAK2PDPK1TGFBR1AURKAAURKB | |
| SCHEMBL4496544 | 0.76 | PDPK1 (0.64) | JAK2PDPK1TGFBR1AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506176-B1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PFIZER ITALIA SRL (IT) | 2013-04-24 | — | — | EP | disclosed |
| US-7632854-B2 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2009-12-15 | — | — | US | disclosed |
| US-20060106083-A1 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2006-05-18 | — | — | US | disclosed |
| EP-1506176-A1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pharmacia Italia S.p.A. (IT) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003097610-A1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106083-A1 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K15, MAP3K3, MAP3K20 | JAK2 416/4885PDPK1 34/4885TGFBR1 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.